Not every registration holder submits a PSUR in the EAEU. Who is exempt and what deadlines apply to everyone else


A periodic safety update report (PSUR) assesses the benefit-risk balance of a medicinal product at defined stages of the post-registration period. The requirements for it are set by Decision of the Council of the Eurasian Economic Commission (EEC) No. 87 (hereinafter Decision No. 87).
Under Decision No. 87, the registration holder of a generic medicine, a medicine with well-established medical use, or a herbal or homeopathic medicine that is registered in the member states or brought into line with Union requirements (dossier alignment) does not submit a PSUR, except in three cases. Other registration holders submit a PSUR according to the list approved by the authorized bodies of the member states. For substances outside the list, the default schedule applies.
In the Russian Federation, the report is reviewed under the Pharmacovigilance Procedure approved by Order No. 3518 of the Federal Service for Surveillance in Healthcare, or Roszdravnadzor (hereinafter Order No. 3518). The Order is in force from 1 March 2025 to 1 March 2031. If the expert organization (a federal state budgetary institution subordinate to Roszdravnadzor) finds three times in a row that a PSUR for one medicinal product does not meet the report requirements, Roszdravnadzor decides whether to conduct an unscheduled inspection of the registration holder’s pharmacovigilance system.

What a PSUR must show

The main objective of the report is an exhaustive analysis of the benefit-risk balance of the medicinal product, taking into account all new safety data and their cumulative impact on the safety or efficacy profile.
A PSUR is not meant for urgent communications: not for the immediate submission of important safety or efficacy information, and not for identifying new safety information. If an emerging safety issue arises, the registration holder sends the information to Roszdravnadzor within 3 working days by e-mail, followed by a mandatory hard copy.
For each active substance or combination of substances, the registration holder prepares one PSUR. It covers all of the holder’s medicinal products with that substance or combination, and all approved indications, routes of administration, dosage forms and dosing regimens. The benefit-risk analysis rests on cumulative data from the date of the first registration of the medicinal product or the date of the first authorization of an interventional clinical trial in any state.
The report consists of a title page, an executive summary and a table of contents of 20 sections, from the introduction to the appendices. The title page states the name of the medicinal product and the active substance, the international birth date, the reporting interval, the date of preparation, the registration holder’s details and a confidentiality note. The title page is signed by the Qualified Person for Pharmacovigilance (QPPV) or by the person to whom the function of approving the report has been delegated. If the registration holder does not know the actual international birth date (IBD), it consults the lists of published international birth dates. If the medicinal product is not on any list, the registration holder agrees with the authorized body on using the first known date of obtaining a registration certificate for the active substance.
Section 5 of the report covers the number of patients exposed to the medicinal product. It calls for an accurate estimate of that number, with data on sales volume and the number of prescriptions. If the number of patients cannot be calculated, the registration holder explains why and uses alternative metrics: patient-days or the number of prescriptions. An estimate based on sales volume is allowed only when those metrics are unavailable.
The report is submitted electronically in a text-searchable format, in Russian or English. The authorized bodies of the member states evaluate the report. English is allowed for the body of the report, but the executive summary, the benefit-risk analysis for the approved indications and the conclusion must be in Russian from the outset. The registration holder must submit a Russian translation of the remaining sections within 30 calendar days of receiving a request from the authorized body.

Who must submit a PSUR and within what deadlines

The frequency and deadlines are set by the list that the authorized bodies of the member states approve. On 6 March 2025, Roszdravnadzor published on its website a draft list of PSUR frequencies and deadlines and is accepting comments on it. The draft comes with a file of two sheets: 3,245 international nonproprietary names (INNs) with the submission frequency, the data lock point and the submission date, and 469 trade names, mostly homeopathic. The draft page gives no act details or approval date. For medicinal products whose international nonproprietary name or grouping name is not on the list, the default schedule from Decision No. 87 applies. The deadline is counted from the data lock point. This is the date when data collection for the report ends; it is based on the international birth date and includes a day and a month (Table 1).

Table 1. PSUR submission frequency and deadlines

SituationFrequencyDeadline
Substance not on the listEvery 6 months from the IBD during the first 2 years, annually during the next 2 years, then every 3 yearsNo more than 90 calendar days from the data lock point
Substance on the listAccording to the listAccording to the list
Ad hoc PSUROn written request of the authorized bodyPreparation takes no more than 60 calendar days from receipt of the request
Translation of the remaining sections into RussianOn request of the authorized body30 calendar days from receipt of the request

Under Decision No. 87, generic medicines, medicines with well-established medical use, and herbal and homeopathic medicines registered in the member states or brought into line with Union requirements do not submit a PSUR, except in three cases:
the obligation to submit a PSUR was set at registration of the medicinal product by the authorized body (expert organization) of the reference state;
the obligation was set on the basis of data identified by the pharmacovigilance system;
the member state has no registered original medicinal product (for generic medicines).

An authorized body is entitled to request a PSUR from the registration holder of such a medicinal product as well. The exemption from regular submission leaves the other obligations in place: the registration holder carries out all procedures for continuous safety monitoring throughout the life cycle of the medicinal product and submits to the authorized body without delay all information that may affect the assessment of the benefit-risk balance.
In the Russian Federation, this exemption under Decision No. 87 applies to medicinal products registered under Union rules or brought into line with them. For other medicinal products, the frequency and deadlines are set by the list and the default schedule from Decision No. 87, as the Pharmacovigilance Procedure states.

How Roszdravnadzor reviews a PSUR

A PSUR that the registration holder submits through the automated information system of Roszdravnadzor (Roszdravnadzor AIS) is registered in it automatically. The report must meet the PSUR requirements of Decision No. 87. The expert organization evaluates the scientific and clinical information in the report within 60 working days from the date the report reaches the expert organization (Table 2).

Table 2. Deadlines after PSUR submission under the Pharmacovigilance Procedure

EventDeadline
Expert organization evaluates the PSUR60 working days from receipt by the expert organization
Information on the rejection is entered in the Roszdravnadzor AIS, and the registration holder receives a notification in the personal account5 working days from the date the expert opinion is issued
Registration holder sends the corrected PSURNo more than 30 working days from receipt of the notification
Expert organization informs Roszdravnadzor of the third consecutive non-compliance for one medicinal product5 working days from the date the opinion is issued
Roszdravnadzor considers whether to request an ad hoc PSUR5 working days from the date it identifies the information or the breach of the submission requirements

The expert organization rejects a PSUR if it does not meet the report requirements of Decision No. 87. The three consecutive non-compliances are counted per medicinal product. On receiving this information, Roszdravnadzor decides whether an unscheduled inspection of the registration holder’s pharmacovigilance system for that medicinal product is needed.
If the opinion of the expert organization contains new safety data that are absent from the Summary of Product Characteristics or the package leaflet and that change the benefit-risk balance, Roszdravnadzor notifies the registration holder in the personal account in the Roszdravnadzor AIS within 5 working days from the date the opinion is issued. Within 10 working days from receipt of the notification, the registration holder analyzes the reliability of the information and submits the results to Roszdravnadzor; if a more detailed check is needed, the registration holder submits within the same 10 working days a preliminary answer on whether urgent measures are needed. Then, within 30 working days from receipt of the analysis results or from the end of the period set for the analysis, Roszdravnadzor decides whether to send the registration holder a request to develop a risk management plan (RMP), and the RMP is sent within 60 working days from receipt of the request.
If the opinion of the expert organization finds the medicinal product dangerous (serious or irreparable harm to health, a proven unfavorable benefit-risk balance, documented insufficient efficacy), or if the registration holder has not met its pharmacovigilance obligations or the requirements of the authorized body set at registration, Roszdravnadzor sends information to the Russian Ministry of Health within 5 working days from receipt of the opinion for suspension of the registration certificate or restriction of the use of the medicinal product.

What to do

Compile a register of the active substances in your portfolio. For each substance, record the IBD, the data lock point, the date of the next submission and the legal status of the registration certificate: registered under Union rules, brought into line with them, or falling under the remaining cases.
Sort the substances into three groups:
submission according to the list or the default schedule;
exemption under Decision No. 87;
exemption to which one of the three exceptions applies, which means submission is mandatory.

Count the deadlines from the data lock point. For substances outside the list, the final submission deadline is 90 calendar days. Set the internal sign-off date for the QPPV earlier: the margin is needed for internal approval of the report and for translating the three mandatory sections.
Assign data sources to departments. Ask the commercial unit for patient-days and the number of prescriptions, and keep sales volume as the reserve metric. The clinical department supplies study data, and the pharmacovigilance department prepares signals and literature. For a report in English, plan for translating the three sections into Russian.
Check the report against the criteria of the expert organization. The expert organization checks a PSUR against the report requirements of Decision No. 87. Build a checklist from those requirements and add the risks that the registration holder’s quality system under Decision No. 87 must exclude: failure to submit the report, breach of the schedule or submission deadlines without prior agreement with the authorized body, unjustified failure to provide requested information, poor quality of the report, and submission of a report that does not reflect earlier requests from authorized bodies. Before signing, have a second employee review the report.
Set out in a standard operating procedure (SOP) the response to a rejection and a separate channel for urgent information. Appoint an employee to check the personal account in the Roszdravnadzor AIS, and keep a log of rejections for each medicinal product to track the count up to three. Record the deadline of 30 working days for the corrected PSUR. In a separate clause, set out the notification of an emerging safety issue within 3 working days. A PSUR is not used for this.


Regulatory framework:

1. Decision of the EEC Council No. 87 of 3 November 2016 «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union» (as amended on 19 May 2022)
2. Order of the Federal Service for Surveillance in Healthcare No. 3518 of 17 June 2024 «On Approval of the Procedure for Pharmacovigilance of Medicinal Products for Medical Use» (registered with the Russian Ministry of Justice on 5 September 2024, No. 79394; in force from 1 March 2025 to 1 March 2031)
3. Draft list of PSUR frequencies and deadlines for medicinal products, published by Roszdravnadzor on 6 March 2025 (https://roszdravnadzor.gov.ru/documents/86412); no act details, not approved

This page in Russian→